Furthermore, increased LRRK2 kinase activity was observed in post-mortem brain tissue and immune cells of idiopathic PD patients, providing clinical significance of LRRK2 as a therapeutic target [58,59,60]. This evidence concerns the gene LRRK2 and Parkinson disease.